Document is current

Article History

Received: 5 July 2024

Accepted: 7 April 2025

First Online: 21 April 2025

Declarations

:

: The study was conducted in accordance with Good Clinical Practice guidelines, and the Declaration of Helsinki and its subsequent amendments. The study was approved by the Research Ethics Committee CEIC Hospital Clínico San Carlos (Madrid), which served as the Institutional Review Board for all participating centres. The study protocol was also approved by the Spanish Agency of Medicines and Medical Devices.

: Not required.

: MV-A has received grants and personal fees from Roche, personal fees from Merck, Amgen, Sanofi, Servier, Celgene, MSD and Bayer and honoraria for speaker/consulting roles from Amgen, Bayer, Merck, MSD, Roche, Sanofi and Servier. BGS has received travel grants from Amgen, Astra Zeneca, Merck, and Servier, and grants from Amgen, Sanofi, Gilead, Celgene, Bristol Myers Squibb, and Amgen. JS has done speaking honoraria for Ipsen, Lilly, Merck, MSD, Pfizer, Roche, Shire, and Servier, advisory roles for Amgen, Bayer, Bristol-Myers Squibb, Celgene, Ipsen, Merck, Roche, Sanofi, and Servier, and received travelling and accommodation support from Ipsen and Merck. FR has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events fromRoche, Merck-Serono, AMGEN, Sanofi-Aventis, Servier, MSD, and Support for attending meetings and/or travel from Roche, MSD, and Servier. PG-A has received payment as speaker’ bureau for Amgen, Roche, Merck-Serono, MSD, Sanofi-Aventis, Pierre Fabre and Servier and received travel, accommodations and expenses from Amgen, Roche, Merck-Serono, Sanofi-Aventis, MSD, Pierre Fabre and Servier and payments from advisory activities from Amgen, Roche, Merck-Serono, MSD, Sanofi-Aventis, Pierre Fabre and Servier. RLL has stock and other ownership interests in MTrap and Nasasbiotech SL, and received consulting or advisory payments for Bayer, Bristol-Myers Squibb, Janssen, Lilly, MSD, Roche, and Novartis, received institutional research funding from Lilly, Merck, and Roche, and r travel, accommodation, and expenses from Pierre Fabre, Roche and Tesaro. CG-P has received travel, accommodation, and expenses from Sanofi/Aventis. ED-R has done consulting or advisory roles for Amgen, Bayer, Genomica, Merck Serono and Servier, speakers’ bureaus for MSD and Servier, and received research funding from Amgen, AstraZeneca, Merck Serono, Roche and Sysmex. EA has received honoraria for advisory role from Amgen, Bayer, Sanofi, Incyte and Pierre Fabre. MT-F, PJ-F, GP-C, SG, AS, MS, AR-A, JMV declare no potential conflicts of interest.